QUALITY OF LIFE OUTCOMES FROM PURSUIT-M TRIAL FURTHER SUPPORT EARLY DOSE OPTIMIZATION OF GOLIMUMAB IN MODERATE-TO-SEVERE ACTIVE ULCERATIVE COLITIS

Amy Puenpatom ¹ Ping Xu ² Anjela Tzontcheva ² Tony Terzis ³ Alan Meehan ⁴ Cindy L J Weinstein ⁴
¹ Merck & Co., Inc., Upper Gwynedd, United States
² Merck & Co., Inc., Rahway, United States
³ MSD Switzerland, Kriens, Switzerland
⁴ Merck & Co., Inc., Kenilworth, United States

Session
IBD (Posters)

Conference
UEG Week Virtual 2020

Citation
United European Gastroenterology Journal 2020; 8 (Supplement 1)

Do you need help setting up your myUEG account?
Contact us at [email protected]

Social Sharing